BHVN
Biohaven Ltd. · Healthcare
9.39
0.11%(+0.01)
Market OpenLast Updated: — ET
52W L: $7.4852W H: $24.06
Biohaven Ltd. · Healthcare
Insider Activity
Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE: BHVN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 693,452 shares of the company's stock, valued at approximately $7,829,000. Aberdeen Group plc owned 0.66% of Biohaven as
SG Americas Securities LLC grew its holdings in shares of Biohaven Ltd. (NYSE: BHVN) by 291.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,518 shares of the company's stock after buying an additional 78,585 shares during the
Sarissa Capital Management added 513,184 shares in Biohaven during the fourth quarter. The quarter-end position value increased by $5.79 million as a result of the transaction.
Biohaven Ltd. (NYSE: BHVN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seventeen brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and three have given a
DAFNA Capital Management bought 720,000 shares of Biohaven in the fourth quarter; the estimated trade size was $8.92 million, based on average prices in the fourth quarter of 2025. Meanwhile, the quarter-end value of the position rose by $7.25 million, reflecting both the share increase and stock price changes during the period.
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity.
Mehta Kishan
director
17,342 SH @ $0.00
2026-03-17
Mehta Kishan
director
17,342 SH @ $0.00
2026-03-17
CHILDS JOHN W
director
28,400 SH @ $30.43
2025-03-04
Buten Matthew
officer: Chief Financial Officer
175,000 SH @ $11.52
2026-02-27
Gentile Kimberly
officer: SVP, Clinical Operations
175,000 SH @ $11.52
2026-02-27
Clark George C.
officer: VP, Chief Accounting Officer
50,000 SH @ $11.52
2026-02-27
Car Bruce
officer: Chief Scientific Officer
175,000 SH @ $11.52
2026-02-27
Coric Vlad
director, officer: Chief Executive Officer
550,000 SH @ $11.52
2026-02-27